These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 18555236)

  • 1. No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles.
    Hernández ER; Gómez-Palomares JL; Ricciarelli E
    Fertil Steril; 2009 Apr; 91(4 Suppl):1358-61. PubMed ID: 18555236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The optimal length of 'coasting protocol' in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization.
    Nardo LG; Cheema P; Gelbaya TA; Horne G; Fitzgerald CT; Pease EH; Brison DR; Lieberman BA
    Hum Fertil (Camb); 2006 Sep; 9(3):175-80. PubMed ID: 17008270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of human chorionic gonadotropin and gonadotropin-releasing hormone agonist for final oocyte maturation in oocyte donor cycles.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Ross R
    Fertil Steril; 2007 Jul; 88(1):237-9. PubMed ID: 17296193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support.
    Castillo JC; Dolz M; Bienvenido E; Abad L; Casañ EM; Bonilla-Musoles F
    Reprod Biomed Online; 2010 Feb; 20(2):175-81. PubMed ID: 20113955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oocyte quality and IVF outcome after coasting to prevent ovarian hyperstimulation syndrome.
    Delvigne A; Kostyla K; Murillo D; Van Hoeck J; Rozenberg S
    Int J Fertil Womens Med; 2003; 48(1):25-31. PubMed ID: 12643517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incidence of both serious and minor complications in young women undergoing oocyte donation.
    Maxwell KN; Cholst IN; Rosenwaks Z
    Fertil Steril; 2008 Dec; 90(6):2165-71. PubMed ID: 18249368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting.
    Ho Yuen B; Nguyen TA; Cheung AP; Leung PC
    Fertil Steril; 2009 Aug; 92(2):499-507. PubMed ID: 18706551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction.
    Cerrillo M; Rodríguez S; Mayoral M; Pacheco A; Martínez-Salazar J; Garcia-Velasco JA
    Fertil Steril; 2009 Apr; 91(4 Suppl):1526-8. PubMed ID: 18990367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the preferred GnRH analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in vitro fertilization?
    Orvieto R; Meltcer S; Homburg R; Nahum R; Rabinson J; Ashkenazi J
    Fertil Steril; 2009 Apr; 91(4 Suppl):1466-8. PubMed ID: 18774558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates.
    Acevedo B; Gomez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2006 Dec; 86(6):1682-7. PubMed ID: 17074344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of coasting on IVF cycle characteristics and outcome in short vs. long GnRH agonist protocols.
    Farhi J; Fisch B; Sapir O; Pinkas H; Ben-Haroush A
    Gynecol Endocrinol; 2010 Mar; 26(3):187-92. PubMed ID: 20148740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study.
    Bodri D; Guillén JJ; Trullenque M; Schwenn K; Esteve C; Coll O
    Fertil Steril; 2010 May; 93(7):2418-20. PubMed ID: 19800620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study.
    Schachter M; Friedler S; Ron-El R; Zimmerman AL; Strassburger D; Bern O; Raziel A
    Fertil Steril; 2008 Oct; 90(4):1087-93. PubMed ID: 18023439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basic understanding of gonadotropin-releasing hormone-agonist triggering.
    Casper RF
    Fertil Steril; 2015 Apr; 103(4):867-9. PubMed ID: 25712575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study.
    Giles J; Requena A; García-Velasco JA; Pacheco A; Pellicer J; Pellicer A
    Fertil Steril; 2009 Apr; 91(4 Suppl):1366-9. PubMed ID: 18692821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH.
    Martínez F; Boada M; Coroleu B; Clua E; Parera N; Rodríguez I; Barri PN
    Hum Reprod; 2006 Aug; 21(8):2121-5. PubMed ID: 16632462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome.
    Cerrillo M; Pacheco A; Rodríguez S; Gómez R; Delgado F; Pellicer A; Garcia-Velasco JA
    Fertil Steril; 2011 Jun; 95(8):2517-9. PubMed ID: 21269615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.